Background-Risk stratification and the use of specific biomarkers have been proposed for tailoring treatment in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). We investigated the prognostic importance of highsensitivity troponin T (hs-TnT), N-terminal pro-brain natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) in relation to randomized treatment (ticagrelor versus clopidogrel) and management strategy (with or without revascularization) in the NSTE-ACS subgroup of the Platelet Inhibition and Patient Outcomes (PLATO) trial. Methods and Results-Of 18 624 patients in the PLATO trial, 9946 had an entry diagnosis of NSTE-ACS and baseline blood samples available. During index hospitalization, 5357 were revascularized, and 4589 were managed without revascularization. Hs-TnT, NT-proBNP, and GDF-15 were determined and assessed according to predefined cutoff levels. Median follow-up was 9.1 months. Increasing levels of hs-TnT were associated with increasing risk of cardiovascular death, myocardial infarction, and stroke in medically managed patients (P<0.001), but not in those managed invasively. NT-proBNP and GDF-15 levels were associated with the same events independent of management strategy. Ticagrelor versus clopidogrel reduced the rate of cardiovascular death, myocardial infarction, and stroke in patients with NSTE-ACS and hs-TnT ≥14.0 ng/L in both invasively and noninvasively managed patients; in patients with hs-TnT <14.0 ng/L, there was no difference between ticagrelor and clopidogrel in the noninvasive group Conclusions-Hs-TnT, NT-proBNP, and GDF-15 are predictors of cardiovascular death, myocardial infarction, and stroke in patients with NSTE-ACS managed noninvasively, and NT-proBNP and GDF-15 also in those managed invasively. Elevated hs-TnT predicts substantial benefit of ticagrelor over clopidogrel both in invasively and noninvasively managed patients, but no apparent benefit was seen at normal hs-TnT. Clinical Trial Registration-URL:http://www.clinicaltrials.gov. Unique identifier: NCT00391872. [3] [4] [5] using the invasive approach only in the case of remaining signs or symptoms of ischemia. 6, 7 To select the most appropriate strategy, both clinical risk scores and the use of biomarkers have been advocated. Over the past decades, elevated levels of troponin, [8] [9] [10] N-terminal probrain natriuretic peptide (NT-proBNP), 11, 12 and growth differentiation factor-15 (GDF-15) [13] [14] [15] have been associated with worse outcome and benefit of an early invasive strategy. Elevated levels of troponin have also been found to identify those with larger benefit from antithrombotic treatment, eg, glycoprotein IIb/IIIa inhibitors, 16 and low-molecular-weight heparins.
D espite guideline recommendations of invasive treatment, 1,2 a substantial proportion of patients with non-STelevation acute coronary syndrome (NSTE-ACS) and elevated troponin is managed without early invasive procedures, [3] [4] [5] using the invasive approach only in the case of remaining signs or symptoms of ischemia. 6, 7 To select the most appropriate strategy, both clinical risk scores and the use of biomarkers have been advocated. Over the past decades, elevated levels of troponin, [8] [9] [10] N-terminal probrain natriuretic peptide (NT-proBNP), 11, 12 and growth differentiation factor-15 (GDF-15) [13] [14] [15] have been associated with worse outcome and benefit of an early invasive strategy. Elevated levels of troponin have also been found to identify those with larger benefit from antithrombotic treatment, eg, glycoprotein IIb/IIIa inhibitors, 16 and low-molecular-weight heparins. 17 Currently, troponin is the only biomarker recommended to be included among the factors used for decision support in the treatment guidelines.
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The Platelet Inhibition and Patient Outcomes (PLATO) trial recently showed that the oral P2Y 12 -inhibitor ticagrelor, in comparison with clopidogrel, reduced the incidence of cardiovascular (CV) death, myocardial infarction (MI), and stroke in 18 624 patients with NSTE-ACS or ST-elevation ACS during 6 to 12 months of treatment. 3 The study included a biomarker substudy where a prespecified objective was to evaluate if entry levels of a specific biomarker might identify patient groups with different effects of ticagrelor compared with clopidogrel. In the present study, we investigated the prognostic importance of high-sensitivity troponin T (hs-TnT), NT-proBNP, and GDF-15 in relation to randomized treatment (ticagrelor in comparison with clopidogrel) managed with or without revascularization in the NSTE-ACS subgroup of the PLATO trial.
Methods
Details of the design, patients, and outcome definitions, and results for the overall PLATO study have been published. 3, 5 The PLATO trial enrolled in total 18 624 patients presenting with ACS from 43 countries between October 2006 and July 2008. The present study focused on the 9962 patients who fulfilled the criteria for NSTE-ACS and also at randomization provided blood samples for biomarker analyses. NSTE-ACS was defined as the absence of ST-segment elevation or new left bundle-branch block; and at least 2 of the following 3 were required for eligibility: (1) ST-segment depression or transient elevation ≥ 1 mm in ≥2 contiguous leads, (2) positive biomarker of myocardial necrosis, (3) and 1 additional risk factor. 5 The most important exclusion criteria included contraindication to clopidogrel, fibrinolytic therapy within 24 hours, need for oral anticoagulation therapy, need for dialysis, and clinically important anemia or thrombocytopenia. The trial was approved by ethical review boards and adhered to the ethical principles of the Declaration of Helsinki. All patients gave a written informed consent.
Study Medication
Patients were randomly assigned to treatment with ticagrelor or clopidogrel. Ticagrelor was given with a loading dose of 180 mg followed by 90 mg twice daily. Patients randomly assigned to clopidogrel who had not received an open-label loading dose and had not been taking clopidogrel for at least 5 days before randomization received a 300-mg loading dose of clopidogrel study drug followed by 75 mg daily. Others continued on a maintenance dose of 75 mg of clopidogrel daily. All patients received acetylsalicylic acid unless intolerant. The randomized treatment continued from a minimum of 6 to a maximum of 12 months with a median duration of study treatment of 9.1 months in the overall population.
Definition of Invasive or Noninvasive Treatment
At the time of randomization, patients were designated as planned for initial invasive or initial conservative management by the treating physician within the interactive voice randomization system. However, this initial decision was not binding and frequently changed during hospital stay. For this analysis, we therefore classified the patients as in-hospital invasive if percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) was performed during the initial hospital stay, and otherwise as in-hospital noninvasive.
Outcome Events
The primary outcome variable was time to first occurrence of any event from the composite of CV death, MI, or stroke. Other outcome variables included CV death and MI, the individual components of the primary composite, and total death. The MI events were also classified post hoc according to the universal MI definition from 2007 18 before the revised definition published in 2012 19 as either (1) all MI not associated with PCI, CABG, stent thrombosis, or death; (2) MI associated with death (type 3); (3) MI associated with PCI (type 4a); (4) MI associated with stent thrombosis (type 4b); or (5) MI associated with CABG (type 5). In these analyses the separate types of MI were stratified into spontaneous (nonprocedure-related) MI and directly procedure-related (type 4a or type 5) MI. The reason for the latter approach was the difference in long-term clinical consequences between spontaneous and periprocedural events, 20 the need to include nonclassifiable "silent" MI, and the influence of admission levels of hs-TnT on the possibility to diagnose periprocedural events. All events were centrally adjudicated and classified by an independent adjudication committee using previously published definitions.
3,5
Biomarkers -Sampling and Methods
Blood samples were obtained via a direct venous puncture from patients providing informed consent for the biomarker substudy at randomization. This was at a median of 15 hours (Q1-Q3 8-21 hours) after the index event, or 10 hours (Q1-Q3 3-17 hours) after admission. Plasma was frozen in aliquots and stored at -70°C until analyzed centrally at the Uppsala Clinical Research Center laboratory. Hs-TnT (lot number 153 401), NT-proBNP, and GDF-15 were determined with sandwich immunoassays on the Cobas Analytics e601 and c501 Immunoanalyzer (Roche Diagnostics) according to the instructions of the manufacturer. The Elecsys GDF-15 precommercial assay (Roche Diagnostics) is composed of a monoclonal mouse antibody for capture and a monoclonal mouse antibody fragment (F(ab′) 2 ) for detection, and uses a sandwich assay format. Detection is based on an electrochemiluminescence immunoassay, using a ruthenium(II) complex label. 6 The precommercial assay correlates closely with a previously established immunoradiometric assay method 21 (r=0.9801, regression Passing/Bablok: slope, 1.049; intercept, −136 ng/L). The assay is reported to have an interassay coefficient of variation of 2.3% at 100 ng/L and 1.8% at 17 200 ng/L. The intra-assay coefficient of variation was 0.8% at 1100 ng/L and 0.9% at 18 600 ng/L. The lower detection limit was <10 ng/L (information by Roche Diagnostics).
Statistical Analysis
Baseline characteristics were summarized by using frequencies for categorical variables and medians with interquartile intervals for continuous variables. For test of differences among groups, the χ 2 test or Fisher exact test was used for categorical variables, and the Wilcoxon rank sum test was used for continuous variables. The tested cutoff levels of the biomarkers for discriminative purposes were based on previous studies (hs-TnT, 14.0 ng/L; NT-proBNP, 400 and 1000 ng/L; and GDF-15, 1200 and 1800 ng/L). 13, 14, [22] [23] [24] Also, quartiles of the distribution in the current material were investigated as sensitivity analyses.
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The treatment effects in relation to the levels of the biomarkers were evaluated with a Cox proportional hazards model within the in-hospital invasive and noninvasive treatment groups, respectively.
Biomarkers and their interaction with the randomized treatment were entered as dependent variables by using dummy variables. In all models, age, sex, diabetes mellitus, smoking status, hypertension, Values are proportion (%) or median (interquartile range). ACE indicates angiotensin-converting-enzyme; ARB, angiotensin II receptor blockers; CABG, coronary artery bypass grafting; GDF-15, growth differentiation factor-15; hs-TnT, high-sensitivity troponin T; NSTE-ACS, non-ST-elevation acute coronary syndrome; NT-proBNP, N-terminal pro-brain natriuretic peptide; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack; and TIMI, Thrombolysis in Myocardial Infarction.
*P values from χ congestive heart failure, peripheral arterial disease, previous MI, previous PCI, previous CABG, ST depression in ECG at entry, and the declaration of planned invasive or noninvasive treatment at randomization were included. The results from the models were presented as estimated hazard ratios, with 95% confidence intervals, of the treatment effect of ticagrelor using clopidogrel as reference. The treatment hazard ratios were reported for each level of the biomarker, regardless of the significance of interaction. The proportional hazards assumption, with respect to the cardiac biomarkers, was assessed by visual inspection of log-cumulative hazard plots. Kaplan-Meier curves were estimated for the time to event for each cutoff range of the biomarker and the log-rank test was calculated. All analyses were performed by using SAS version 9.2. A P value of 0.05 was used as a critical value determining statistical significance, and there were no adjustments for multiple comparisons.
Results
In the PLATO trial, 9946 patients had an entry diagnosis of NSTE-ACS and provided plasma samples for analyses of all biomarkers, allowing inclusion in the present study. Baseline characteristics by randomized treatment and management strategy are shown in the Table. The randomized treatment groups were balanced within the respective in-hospital invasively and noninvasively managed patients, with the exception that there were somewhat more smokers in the clopidogrel group in the in-hospital noninvasive arm. As expected, there were differences in characteristics in relation to the inhospital invasive or noninvasive treatment. Patients treated invasively were more often male and habitual smokers, and reported less hypertension, diabetes mellitus, previous angina pectoris, MI, heart failure and stroke, but more often previous PCI. At entry, the invasively managed patients less often had ST-segment depression but more often had troponin elevation and higher Thrombolysis in Myocardial Infarction NSTE-ACS risk score.
Biomarkers and Effects of Ticagrelor in the In-Hospital Noninvasive Group
In patients managed without revascularization, hs-TnT levels were significantly related to the rate of the primary composite end point of CV death, MI, and stroke (log-rank P<0.001), driven by associations both with CV death and spontaneous MI (Figures 1 and 2 ) corresponding mainly to type 1 to 3 MI (Table I in the online-only Data Supplement). Ticagrelor versus clopidogrel reduced the composite of CV death, MI, and stroke with a larger effect in the patients in the upper tertiles of positive hs-TnT levels, ie, those with a higher risk, whereas there was a lack of effect in those with negative hs-TnT (<14 ng/L) (interaction P=0.042) ( Figure 1 ). As shown in Figure 3 , the treatment effect of ticagrelor in the noninvasive cohort with hs-TnT ≥14 ng/L was dominated by a reduction in CV mortality. In the same cohort, there also appeared numeric reductions in all types of MI, with the exception of Increasing levels of NT-proBNP and GDF-15 were associated with increasing risk for CV death, MI, and stroke based on relations to both CV death and spontaneous MI (Figures 1  and 2 ; log-rank P<0.001). There was no significant interaction between the relative reduction of these events with ticagrelor in comparison with clopidogrel and the levels of these markers. Increasing levels of NT-proBNP and GDF-15 were associated with increasing risk of major non-CABG-related bleeding, but there was no significant interaction between the biomarker levels and treatment ( Figure I in the online-only Data Supplement).
Biomarkers and Effects of Ticagrelor in the In-Hospital Invasive Group
In the in-hospital revascularization group, the level of hs-TnT showed no relationship with the rate of the primary composite end point (Figure 4) , the composite of CV death/spontaneous MI (Figure 2) , CV death alone, spontaneous MI alone, or any of the different types of MI (Table II in the online-only Data Supplement). Ticagrelor substantially reduced the rate of the primary composite and its individual components in the inhospital invasive cohort ( Figure 5 ). Numerically there was a larger relative reduction in patients with elevated than normal hs-TnT levels, although not significant in the interaction analysis (Figures 4 and 5) . There was no association between the hs-TnT level and the risk of major non-CABG bleeding and no interaction with the effect of ticagrelor in comparison with clopidogrel ( Figure II in the online-only Data Supplement). The levels of NT-proBNP and GDF-15 were significantly related to the rate of CV death, MI, and stroke (log-rank P<0.001) based on relations to both CV death and spontaneous MI in the in-hospital invasive group (Figures 2 and 4) . There was no significant interaction between the reduction of these events with ticagrelor in comparison with clopidogrel and the levels of these markers (Figure 4) .The relative reduction of these events with ticagrelor in comparison with clopidogrel in the inhospital invasive group was consistent regardless of the levels of these markers. As in the noninvasive group, the absolute reduction of events with ticagrelor treatment was considerably larger in patients with higher NT-proBNP or GDF-15 levels, ie, in those with highest risk (Figures 2 and 4) . Concerning major non-CABG-related bleeding, there was a significant relationship to the levels of NT-proBNP and GDF-15 with higher rates of bleeding at higher levels. The increase in bleeding events with ticagrelor in comparison with clopidogrel in the invasive group was accordingly larger at higher levels of these biomarkers ( Figure II in the online-only Data Supplement).
Discussion
In the present study of patients with NSTE-ACS managed without in-hospital revascularization, we verified the strong association between baseline level of hs-TnT and the risk of subsequent CV death and mainly spontaneous MI (type 1-3). There was no relation between the hs-TnT level and these outcomes in patients who underwent in-hospital revascularization. Among patients without in-hospital revascularization, the benefit of ticagrelor seemed confined to those with elevated hs-TnT, whereas in patients with in-hospital revascularization there was no significant interaction with the hs-TnT level at entry. This study also verified NT-proBNP and GDF-15 as strong predictors of subsequent CV death and spontaneous MI, regardless of in-hospital revascularization procedures. In addition, patients with higher levels of NT-proBNP or GDF-15 had larger absolute benefits from ticagrelor because of their association with higher risks of subsequent events and lack of interaction with treatment effect. These biomarkers might thus help to tailor treatment with potent P2Y 12 inhibitors in NSTE-ACS, eg, by selecting more intense treatment for troponin-positive patients at intermediate to high risk, regardless of invasive management strategy, and downprioritizing its use in noninvasively managed patients with normal hs-TnT levels.
The finding that more intense platelet inhibition with ticagrelor (in comparison with clopidogrel) is effective mainly in troponin-positive patients is in accordance with Figure 4 . Efficacy of ticagrelor relative to clopidogrel on CV death, MI, and stroke in relation to predefined levels of biomarkers at baseline in the in-hospital invasive group. CI indicates confidence interval; CV, cardiovascular; GDF-15, growth differentiation factor-15; HR, hazard ratio; hs-TnT, high-sensitivity troponin T; MI, myocardial infarction; and NT-proBNP, N-terminal pro-brain natriuretic peptide. by guest on September 24, 2017 http://circ.ahajournals.org/ Downloaded from January 21, 2014 similar findings concerning glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins. 16, 17 The usefulness of NT-proBNP and GDF-15 as indicators of the overall longterm cardiovascular and bleeding risk is in accordance with previous experiences with these markers. 11, 12, 14, 15 Although the absolute benefits with both ticagrelor and invasive treatment were larger at higher risk, further work is needed to appropriately evaluate the usefulness of adding these biomarkers to currently established risk scores for decision support.
In contrast to many previous studies, we separately analyzed the relations between the baseline biomarkers, study treatment, and the occurrence of spontaneous or procedure-related events. The relations between biomarkers and outcomes were caused by relations to spontaneous events, ie, CV death and spontaneous (mainly type 1-3) MI. None of the biomarkers had any positive relation with procedure-related (type 4a or type 5) MI.
However, it should be observed that procedure-related events are only possible to diagnose in patients with normal or stable troponin levels before coronary procedures. 18 Some studies have shown a relation of procedure-related MI to long-term outcome, 25, 26 whereas others have shown no or only a weak relation. 20, [27] [28] [29] The reduction of both procedural and spontaneous events by ticagrelor versus clopidogrel in the invasively managed patients may be the main explanation for the lack of significant interaction between hs-TnT and effect of ticagrelor in the in-hospital invasive in contrast to the in-hospital noninvasive group where very few procedural events occurred.
The blood samples for this study were obtained at an average 15 hours after the index event, and therefore reflect the occurrence of any elevation of high-sensitivity troponin, although not necessarily the maximal level in the acute stage. In the present study, a normal level of hs-TnT was the only variable indicating a lack of benefit of ticagrelor in comparison with clopidogrel in NSTE-ACS patients managed without revascularization while in-hospital for the index event. However, more importantly, the study showed that elevation of hs-TnT is associated with a raised risk of CV death and spontaneous MI and a substantial benefit of ticagrelor in comparison with clopidogrel treatment in noninvasively as well as invasively managed patients.
Over the past years, NT-proBNP has appeared as one of the best prognostic markers for outcomes in NSTE-ACS, with an increased rate of subsequent events at elevated levels in both noninvasively and invasively managed patients. 11, 12, 22 However, NT-proBNP levels has not been shown to significantly interact with the outcome of an early invasive strategy. 11, 30 This trial verified that a higher NT-proBNP level was related to a raised risk of future events both in invasively and noninvasively managed patients with NSTE-ACS, but without any interaction with the benefits of ticagrelor in comparison with clopidogrel. Accordingly, a higher NT-proBNP level indicated an increased risk of CV death and spontaneous MI and thereby predicted a greater absolute benefit from ticagrelor treatment.
In recent years, GDF-15 also has appeared as a very consistent marker of adverse long-term outcome in NSTE-ACS. 13, 14 In previous studies of patients with NSTE-ACS, GDF-15 has been found not only to predict future events, but also to contribute to the identification of high-risk patients with a benefit of an early invasive strategy. 13 In the present trial, we verified the usefulness of the previously established cutoff levels for GDF-15 for risk stratification in NSTE-ACS. The GDF-15 level was related to an increased risk of CV death and spontaneous MI, both in the invasively and noninvasively managed patients, but without any interaction with the effect of ticagrelor versus clopidogrel treatment. Thus, a higher GDF-15 level was shown to contribute to the prediction of an increased risk of CV death and spontaneous MI, and thereby to the prediction of a larger absolute benefit from ticagrelor treatment.
Although multiple clinical findings and levels of several biomarkers are related to outcome in patients with NSTE-ACS, only a limited number of variables contribute meaningful information on the effects of specific treatments. [31] [32] [33] [34] In the present study, we found that a normal level of hs-TnT identified patients with limited or no benefit of more intense platelet inhibition, especially in patients managed with a noninvasive treatment approach. The other biomarkers, NT-proBNP and GDF-15, did not show any directional interaction with the effects of ticagrelor treatment, but they contributed information on the magnitude of benefit by a successful intervention such as ticagrelor regardless of invasive or noninvasive management. The complementary contributions from these biomarkers seem logical, with troponin indicating acute plaque instability, thrombus formation, and myocardial damage; NT-proBNP indicating both acute and chronic myocardial stretch and overload; and GDF-15 indicating a chronic condition of cellular stress and need of cellular repair.
Limitations
The stratification of the material according to in-hospital revascularization was a postrandomization clinical decision that, in some instances, might have been influenced by events already occurring before the procedures. However, most differences in the primary outcome events occurred after the procedures, which strengthens the results. In addition, similar results were obtained if the analyses were stratified based on the intended use of an early invasive or noninvasive treatment, as declared by the investigator at randomization (data not shown). The number of patients with normal hs-TnT was small, especially in the in-hospital invasive treatment group, which leads to uncertainty concerning the results in this subgroup. Therefore, the usefulness of different treatments in NSTE-ACS patients with normal hs-TnT needs further exploration.
Conclusions
Hs-TnT, GDF-15, and NT-proBNP are powerful predictors of cardiovascular events in NSTE-ACS managed noninvasively, and NT-proBNP and GDF-15 are also powerful predictors in those managed invasively. Elevated hs-TnT predicts substantial benefit of ticagrelor over clopidogrel, whereas event rates are low and benefits limited, if any, in those with normal hs-TnT. The magnitude of benefit of ticagrelor is related to the degree of elevation of GDF-15 and NT-proBNP, and their use might help tailor treatment with ticagrelor to the appropriate patients. * Spontaneous MI includes also silent MI, which are not possible to classify according to the Type 1 -5 classification system. ** The separation of MI into different types allows several events to occur in the same patient.
